Navigation Links
PDI, Inc. to Hold Fourth Quarter and Full Year 2012 Financial Results Conference Call on Thursday, March 7, 2013
Date:2/28/2013

PARSIPPANY, N.J., Feb. 28, 2013 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that it will release its fourth quarter and full year 2012 financial results on Wednesday, March 6, 2013 after the market close and host a conference call on Thursday, March 7, at 8:30 am Eastern time to discuss the results.Access information:Date:Thursday, March 7, 2013Time:8:30 am Eastern timeDial-in numbers:(866) 644-4654 (U.S. and Canada) or (706) 643-1203 Conference ID number:98411955Live web cast:www.pdi-inc.com, under "Investor Relations"The teleconference replay will be available three hours after completion through March 11, 2013 at (800) 585-8367 (U.S. and Canada) or (404) 537-3406. The replay pass code is 98411955. The archived web cast will be available for one year on the company's web site, www.pdi-inc.com, under "Investor Relations."

About PDI, Inc.PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise. For more information, please visit the company's website at http://www.pdi-inc.com.


'/>"/>
SOURCE PDI, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
2. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
3. BioMed Realty Trust Declares Fourth Quarter 2011 Common Stock and Preferred Stock Dividends
4. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
5. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
6. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
7. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
8. Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
9. Cepheid Reports Fourth Quarter and Full Year 2011 Results
10. BioMed Realty Trust to Report 2011 Fourth Quarter and Year End Results
11. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that ... in Philadelphia, PA. , The presentation took place on Tuesday, June 16 ... for the development of APX3330 for the treatment of pancreatic cancer. A copy ...
(Date:6/30/2015)... /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today ... have approved the resolutions relating to: (i) a ... units at a price of $2.67 per unit ... of one common share and 0.075358 common share ... million; and (ii) the amendment to Resverlogix,s articles ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and OpenBiome Partner for ... of fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome and ... fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. diff). ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... Eindhoven University of Technology (TU/e) have for the ... stages of bone formation. They used the world,s ... of the nano-particles that are at the heart ... of bone, tooth and shell formation. For industrial ...
... 12 Dendreon Corporation (Nasdaq: DNDN ) today ... 2008. Revenues for the year ended December 31, 2008 were ... 2007. Revenues for the fourth quarter of 2008 were $28,000, ... net loss for the year ended December 31, 2008 was ...
... 12 Schering-Plough Corporation (NYSE: SGP ) ... for the 2009 first quarter on Tuesday, April 21, ... Schering-Plough will conduct a conference call to review results ... chairman and CEO, and other members of management will ...
Cached Biology Technology:First high-resolution images of bone, tooth and shell formation 2Dendreon Reports Fourth Quarter and 2008 Year End Financial Results 2Dendreon Reports Fourth Quarter and 2008 Year End Financial Results 3Dendreon Reports Fourth Quarter and 2008 Year End Financial Results 4Dendreon Reports Fourth Quarter and 2008 Year End Financial Results 5
(Date:6/29/2015)... June 24, 2015 Research ... the "Latin America Biomedical Sensors Market - Growth, ... The Latin America Biomedical Sensors market is ... of 2.04% over the period 2014-2020 The ... to the genetic formulation of each individual. These sensors ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool ... toward a healthier, happier life. That,s exactly what USANA,s ... to do. The cutting-edge, portable health program provides a ... solutions to help improve your lifestyle and nutrition. ... dinner and gala Wednesday night, USANA,s THA was honored ...
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... of children with undiagnosed learning disorders, developmental deficits, and ... challenges, which are explored in detail in a reflective ... a peer-reviewed journal published by Mary Ann Liebert, Inc. ... ahead of print at www.liebertpub.com/gtmb ...
... been extinct for 65 million years, newly published data ... is providing invaluable insights into their paleobiology. Ammonites, shelled ... inhabited the oceans for nearly 350 million years. Specimens ... that covered North America during the Cretaceous Period demonstrate ...
... are investigating a potential new treatment for lung disease that ... is studying how statins, drugs which are commonly used to ... , There is currently no effective treatment for acute ... rates for those who become critically ill and suffer lung ...
Cached Biology News:Unexplained childhood disorders 2New discoveries in North America's Great Plains bring ammonites to life 2New discoveries in North America's Great Plains bring ammonites to life 3Queen's University Belfast lung injury study could save lives in critically ill 2
Recombinant Feline IL-12/IL-23 p40...
Request Info...
Recombinant Equine IL-6...
dithiothreitol (DTT) Reactive Dyes and Chemicals Thiol-Reactive Dyes, Haptens and Quenchers Reducing Agents...
Biology Products: